Chimerix CMRX 深 沪
已收盘 04-21 16:00:00 美东时间
8.54
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.54
- 总市值 8.01亿
- 52周最高 8.55
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.75
- 委 比 0.00%
- 总股本 9380.38万
- 历史最高 58.04
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.75
- 每 手 1
- 风险率 2.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
Clearmind Medicine Inc. announced the successful initiation of its Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate targeting Alcohol Use Disorder (AUD), at Tel Aviv Sourasky Medical Center (TASMC). This trial, also conducted at leading US and Israeli institutions, evaluates CMND-100's safety, tolerability, and efficacy in reducing alcohol cravings and consumption. CMND-100, based on the molecule MEAI, has shown promise in pre...
07-23 12:55
Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. expands its Phase I/IIa clinical trial for CMND-100, a psychedelic-derived drug for Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center (TASMC) as a trial site. TASMC joins prestigious institutions like Yale and Johns Hopkins, strengthening the trial's capacity to evaluate CMND-100's safety and efficacy. The trial follows the enrollment of its first patient on June 5. Clearmind aims to address the global...
06-23 11:55
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.
06-04 02:37
Chimerix Terminates Loan and Delists from Nasdaq
The latest announcement is out from Chimerix ( ($CMRX) ). On April 21, 2025, Ch...
04-22 04:52
Jazz Pharmaceuticals Completes Acquisition of Chimerix
- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN, April 21, 2025 /PRNewsw...
04-22 04:05
Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims
Amid a broader selloff in the biopharma sector on Wednesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) dropped ~6% after announcing a $145M settlement to resolve certain antitrust claims filed regarding its ...
04-09 23:46
Top 3 Health Care Stocks That May Crash In Q2
As of April 7, 2025, three stocks in the health care sector could be flashing a...
04-07 23:23
Chimerix Reports 2024 Losses Amid Acquisition News
Chimerix ( ($CMRX) ) has released its Q4 earnings. Here is a breakdown of the i...
03-25 11:52
Chimerix GAAP EPS of -$0.25 beats by $0.01, revenue of $0.06M misses by $0.25M
Chimerix press release (NASDAQ:CMRX): Q4 GAAP EPS of -$0.25 beats by $0.01. Revenue of $57K (vs. $4K Y/Y) misses by $0.25M. Chimerix’s balance sheet at December 31, 2024 included $140.1 million of cap...
03-21 18:07
Chimerix Q4 2024 GAAP EPS $(0.25) Beats $(0.26) Estimate, Sales $57.00K Miss $75.00K Estimate
Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 25 percent decrease over losses of $(0.20) per share from the same
03-21 18:04
